More video interviews from the APCCC in St. Gallen

Our friends at UroToday have just posted another four video interviews from the Advanced Prostate Cancer Consensus Conference at St. Gallen in Switzerland, some of which are likely to be of interest to some of our readers. … READ MORE …

No need to endure 38 to 44 treatments with IMRT anymore

There have been several hypofractionation trials maturing in the last couple of years. With minor exceptions, they all tell the same story: external beam radiation therapy (EBRT) can be completed in less time without loss of efficacy or increase in toxicity. … READ MORE …

Apology for a break in the news feed

While your sitemaster did manage to get himself down to Orlando for the Genitourinary Cancers Symposium, unfortunately he was not at all well while he was there and he is still recovering. He will try to do a little catch up as soon as he is feeling better.

Genitourinary Cancers Symposium: abstracts later today

For those who are interested, the abstracts of all the papers to be presented at this week’s upcoming Genitourinary Cancers Symposium are due to be released by the American Society for Clinical Oncology later today. … READ MORE …

Risk for recurrent prostate cancer: new data

A news item this morning on the NBC web site (and probably elsewhere too) states that a new study just published in JAMA Oncology can help to “determine whether a man’s prostate cancer will come back and kill him after treatment.” We are studying the actual paper and will be commenting on this further later today.

All the lutetium-177 news that’s fit to discuss (when it first comes out)

There has been a lot of noise in the past week about the effectiveness of lutetium-177 linked to PSMA in the treatment of late stage prostate cancer. If you were looking for us to say something about this, Allen Edel already has, back in October last year, when the relevant article was first published on line and Allen promptly commented (click here to get his take).

Axumin-enhanced PET scans becoming more widely available

Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …